Halozyme Therapeutics Inc., a biopharmaceutical technology platform company that focuses on the research, development and commercialization of proprietary enzymes and devices, operates in the United States, Switzerland, Ireland, Belgium, Japan, and internationally. With products based on patented recombinant human hyaluronidase enzyme (rHuPH20), the company facilitates the delivery of injectable biologics including monoclonal antibodies, therapeutic molecules and small molecules, as well as fluids. Notable products include Hylenex recombinant, a formulation of rHuPH20 that enhances the dispersion and absorption of injected drugs, XYOSTED for testosterone replacement therapy, NOCDURNA for the treatment of nocturia, TLANDO for testosterone replacement therapy, ATRS-1902, a drug-device combination product, Herceptin (trastuzumab), Herceptin Hylecta and Phesgo for breast cancer treatment, Mabthera SC for multiple blood cancer treatment, HYQVIA for primary immunodeficiency disorders and DARZALEX for amyloidosis and multiple myeloma treatment. Halozyme Therapeutics also provides solutions for other health concerns including allergies, migraines, arthritis, and severe autoimmune diseases. The company was founded in 1998 and is based in San Diego, California.
Halozyme Therapeutics's ticker is HALO
The company's shares trade on the NASDAQ stock exchange
They are based in San Diego, California
There are 201-500 employees working at Halozyme Therapeutics
It is halozyme.com
Halozyme Therapeutics is in the Healthcare sector
Halozyme Therapeutics is in the Biotechnology industry
The following five companies are Halozyme Therapeutics's industry peers: